Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
These dynamics can rattle even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. That said, here is one mid-cap stock with massive growth potential and two that could be down big.
Two mid-cap stocks to sell:
Repligen (RGEN)
Market cap: $11.39 billion
With over 13 strategic acquisitions since 2012 to build its comprehensive bioprocessing portfolio, Repligen (NASDAQ: RGEN) develops and manufactures specialized technologies that improve the efficiency and flexibility of biological drug manufacturing processes.
Why Should You Sell RGEN?
- Sales trends were unexciting over the last five years as its 6.3% annual growth was below the typical healthcare company
- Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 15.1 percentage points
- Earnings per share have contracted by 5.9% annually over the last five years, a headwind for returns as stock prices often echo long-term EPS performance
At $178.30 per share, Repligen trades at 73x forward P/E. To fully understand why you should be careful with RGEN, check out our full research report (it’s free).
FactSet (FDS)
Market cap: $12.06 billion
Founded in 1978 when financial data was still primarily delivered through paper reports, FactSet (NYSE: FDS) provides financial data, analytics, and technology solutions that investment professionals use to research, analyze, and manage their portfolios.
Why Does FDS Fall Short?
- Annual revenue growth of 6% over the last two years was below our standards for the financials sector
- Incremental sales over the last two years were less profitable as its 4.7% annual earnings per share growth lagged its revenue gains
FactSet is trading at $341.30 per share, or 16.9x forward P/E. Dive into our free research report to see why there are better opportunities than FDS.
One mid-cap stock to watch:
Jack Henry (JKHY)
Market cap: $12.56 billion
Founded in 1976 by two entrepreneurs who saw the need for specialized banking software in the early days of financial computing, Jack Henry & Associates (NASDAQ: JKHY) provides technology solutions that help banks and credit unions innovate, differentiate, and compete while serving the evolving needs of their accountholders.
Why Should JKHY Be on Your Watchlist?
- Share repurchases have increased shareholder returns as its annual earnings per share growth of 15.4% exceeded its revenue gains over the last two years
- Stellar return on equity showcases management’s ability to surface highly profitable business ventures
Jack Henry’s stock price of $178.94 implies a valuation ratio of 21.8x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks we like even more
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
